The majority of Mirum’s revenues are now being driven by Livmarli. In the first nine months of 2024, Livmarli generated sales worth $149.2 million, up 48.7% on a year-over-year basis.

Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI ...

FOSTER CITY, Calif., April 10, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors ...

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative ...